Codes / ICD10CM / C22.0

C22.0 Liver cell carcinoma

ICD10CM code

ICD10CM

Chat with GenHealth to automate any coding or chart task.

Name of the Condition

  • Liver cell carcinoma
  • Hepatocellular carcinoma (HCC)

Summary

Liver cell carcinoma is a type of primary liver cancer that originates in the hepatocytes, the main functional cells of the liver. It is the most common form of primary liver cancer and can impair liver function, potentially spreading to nearby tissues or other organs if not treated. The condition is often associated with underlying liver disease.

Causes

The development of liver cell carcinoma involves genetic mutations in hepatocytes that lead to uncontrolled cell growth. Contributing factors may include chronic liver inflammation, environmental exposures, and genetic predispositions. These mutations disrupt normal cellular regulation, allowing cancerous cells to proliferate.

Risk Factors

  • Chronic viral hepatitis (hepatitis B or C)
  • Cirrhosis of the liver
  • Excessive alcohol consumption
  • Non-alcoholic fatty liver disease (NAFLD)
  • Aflatoxin exposure
  • Age, particularly over 50
  • Male gender
  • Family history of liver cancer
  • Diabetes mellitus

Symptoms

  • Unexplained weight loss
  • Abdominal pain or swelling
  • Jaundice (yellowing of skin/eyes)
  • Loss of appetite
  • Nausea or vomiting
  • Fatigue
  • Dark urine or pale stools
  • Enlarged liver (hepatomegaly)

Diagnosis

Diagnosis begins with a physical examination and assessment of symptoms. Imaging tests (e.g., ultrasound, CT, MRI) are used to detect abnormalities in the liver. A biopsy of liver tissue may be performed to confirm malignancy, and blood tests (e.g., alpha-fetoprotein levels) can support the diagnosis. Additional imaging may evaluate the extent of the cancer.

Treatment Options

Treatment depends on the stage of the cancer, liver function, and overall health. Options may include surgical resection, liver transplantation, ablation (e.g., radiofrequency or microwave), embolization, targeted therapy, immunotherapy, or systemic chemotherapy. Palliative care may be considered for advanced cases.

Prognosis and Follow-Up

Prognosis varies based on the stage at diagnosis, liver function, and treatment response. Early detection improves outcomes, but advanced disease often has a poorer prognosis. Regular follow-up with imaging and blood tests is essential to monitor for recurrence or progression.

Complications

  • Liver failure
  • Metastasis to other organs (e.g., lungs, bones)
  • Portal hypertension
  • Ascites (fluid buildup in the abdomen)
  • Bleeding from esophageal varices
  • Hepatic encephalopathy

Lifestyle & Prevention

  • Limit alcohol consumption
  • Maintain a healthy weight to reduce NAFLD risk
  • Get vaccinated against hepatitis B
  • Avoid exposure to aflatoxins (e.g., contaminated foods)
  • Manage chronic liver conditions (e.g., hepatitis C treatment)
  • Regular screening for high-risk individuals

When to Seek Professional Help

Seek medical attention if you experience persistent abdominal pain, unexplained weight loss, jaundice, or other symptoms of liver dysfunction. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

When coding for liver cell carcinoma (C22.0), ensure documentation specifies the primary site as the liver (hepatocytes) and confirms it is a primary malignancy. Differentiate from secondary liver cancers or other liver conditions. Verify that the diagnosis aligns with clinical findings and imaging results to support accurate coding.

Medical Policies and Guidelines

Related policies from health plans

Cyramza (ramucirumab)
Imfinzi (durvalumab)
Imjudo (tremelimumab-actl)
Opdivo (nivolumab)
Tecentriq (atezolizumab)
Tecentriq (atezolizumab)
Yervoy (ipilimumab)
Yervoy (ipilimumab)
Book a walkthrough

C22.0 policy automation walkthrough

Walk through the policies, prior authorization requirements, and workflow automation opportunities connected to this code.